What is the role of methotrexate as a steroid-sparing agent in a patient with clinically diagnosed giant cell arteritis on prednisone who wishes to limit long-term glucocorticoid exposure?

Methotrexate as Steroid-Sparing Agent in Giant Cell Arteritis

Methotrexate should be considered as an adjunctive steroid-sparing agent in patients with giant cell arteritis who wish to limit long-term glucocorticoid exposure, though tocilizumab is the preferred first-line steroid-sparing option when available. 1

Treatment Algorithm for Steroid-Sparing Therapy

First-Line Steroid-Sparing Agent

• Tocilizumab is preferred for patients with:
  • Refractory or relapsing disease
  • Presence of or increased risk for glucocorticoid-related adverse effects
  • Desire to minimize long-term steroid exposure 1

Methotrexate as Alternative

• Use methotrexate when tocilizumab is not available, not tolerated, or not preferred by the patient 1
• Dosing: 10-15 mg/week orally 2, 3
• Must be combined with at least 5 mg folic acid weekly 2

Evidence for Methotrexate Efficacy

The evidence supporting methotrexate shows modest but real benefits:

Relapse Reduction

A meta-analysis of three randomized controlled trials demonstrates that methotrexate:

• Reduces first relapse risk by 35% (HR 0.65, P=0.04) 4
• Reduces second relapse risk by 51% (HR 0.49, P=0.02) 4
• Number needed to treat: 3.6 patients to prevent one first relapse within 48 weeks 4

Glucocorticoid-Sparing Effect

• Reduces cumulative prednisone dose by approximately 842 mg within 48 weeks 4
• Increases probability of achieving sustained glucocorticoid discontinuation for ≥24 weeks (HR 2.84, P=0.001) 4
• In one RCT, cumulative prednisone dose was reduced by 1,302 mg (4,187 mg vs 5,489 mg, P=0.009) 5

Important Caveats and Contradictory Evidence

Mixed Trial Results

Not all studies show benefit. The largest multicenter trial (98 patients) found no significant difference in treatment failure rates between methotrexate and placebo (57.5% vs 77.3%, P=0.26) 6. However, this study had methodological limitations and the meta-analysis of all three trials still supports modest efficacy 4.

Real-World Data

Recent real-world studies show variable results:

• One cohort showed methotrexate reduced relapse rate by nearly 2-fold compared to glucocorticoids alone 7
• Another real-world study showed only modest benefit with 65% of patients who relapsed before methotrexate experiencing new relapses after its introduction 8

Practical Implementation

When to Initiate Methotrexate

Start methotrexate in patients with:

• Multiple relapses during glucocorticoid taper
• Inability to taper prednisone below 10-15 mg/day
• Significant glucocorticoid-related adverse effects (osteoporosis, diabetes, weight gain, hypertension)
• Patient preference to minimize steroid exposure from the outset 1

Monitoring Requirements

Before starting methotrexate 2:

• AST, ALT, albumin
• Complete blood count
• Creatinine
• Chest x-ray (within previous year)
• Consider hepatitis B/C serology

During treatment 2:

• ALT/AST, creatinine, CBC every 1-1.5 months until stable dose
• Then every 1-3 months thereafter
• Stop if ALT/AST >3× upper limit of normal (confirmed)

Expected Timeline

• Clinical effects on articular symptoms may be seen as early as 3-6 weeks 9
• Continue for at least 12-24 months if effective 5
• Can be used long-term with acceptable safety profile 2

Comparison with Tocilizumab

Tocilizumab is superior to methotrexate based on the 2018 EULAR algorithm 1:

• Tocilizumab allows faster glucocorticoid taper (to <5 mg at 6 months)
• More robust evidence from the GiACTA trial
• Methotrexate listed as "alternative" when tocilizumab not suitable

Safety Profile

Methotrexate is generally well-tolerated in GCA:

• Dropout rates and adverse events similar to placebo in trials 4
• Common side effects: gastrointestinal symptoms, liver enzyme elevations
• Folic acid supplementation (≥5 mg/week) reduces GI and liver toxicity without reducing efficacy 2
• Contraindicated in pregnancy (discontinue ≥3 months before planned conception) 2

Bottom Line for Clinical Practice

For your patient with clinically diagnosed GCA on prednisone wishing to limit glucocorticoid exposure:

1. First choice: Tocilizumab 162 mg subcutaneously weekly (if available and no contraindications) 1

2. Alternative: Methotrexate 10-15 mg/week orally plus folic acid ≥5 mg/week 2, 4

   • Expect modest reduction in relapse risk (35% reduction)
   • Expect modest glucocorticoid-sparing effect (~800-1,300 mg cumulative dose reduction)
   • Monitor liver function and blood counts regularly

3. Set realistic expectations: Methotrexate provides meaningful but not dramatic benefit—it is not as effective as tocilizumab but remains a reasonable option when tocilizumab is not feasible 1, 4